表皮生长因子受体在人头颈部鳞状细胞癌中的作用研究进展

摘要

头颈部鳞状细胞癌(head and neck squamous cell carcinoma,HNSCC)是常见的恶性肿瘤,恶性程度较高,患者常出现复发和转移.表皮生长因子受体(epidermal growth factor receptor,EGFR)是重要的癌基因,在头颈鳞癌中广泛过表达,且与HNSCC患者的预后呈负相关,是重要的治疗靶点.但HNSCC中的EGFR靶向治疗效果却不如在非小细胞肺癌治疗中那么有效.近几年的研究发现,EGFR促进肿瘤细胞对治疗耐受的机制可能与其过表达、突变、单核苷酸多态性、入核和自噬有关.本文将就这几个方面进行综述,并探讨如何在HNSCC的治疗中更有效地利用EGFR这一靶点,为探索HNSCC的治疗策略提供新的方向.%Head and neck squamous cell carcinoma(HNSCC)is a common malignant tumor with a relatively high degree of malignan-cy,which often induces recurrence and metastasis.Epidermal growth factor receptor(EGFR)is an important oncogene that is overex-pressed in HNSCC and is negatively correlated with prognosis,making it an important therapeutic target.However,EGFR-targeted ther-apy for HNSCC is not as effective as it is for non-small cell lung cancer.Recent studies have found that EGFR can promote resistance of tumor cells to therapeutic agents via its overexpression,mutation,single nucleotide polymorphism,nuclear translocation,and induc-tion of autophagy.This article will review these aspects and discuss how to utilize EGFR more effectively in treating HNSCC,and also provide a new direction for exploring therapeutic strategies for HNSCC.